Correction: Advancing Beyond Inhibition: Utilizing the DRD2–VEGF-A Feedback Mechanism
Overview
This correction addresses inaccuracies in the funding statement of the original article regarding the NIH/NCI and DOD USA grants. The corrected funding information specifies support from the Ohio State University Comprehensive Cancer Center.
Background
Accurate funding disclosures are essential for transparency in research. The original article proposed a novel approach to anti-angiogenesis therapy in oncology by utilizing the DRD2–VEGF-A feedback loop. Understanding the funding sources is critical for evaluating potential biases in research findings.
Data Highlights
No numerical or trial data was presented in the source material.
Key Findings
The original article incorrectly listed unrelated NIH/NCI and DOD USA grants.
The corrected funding statement clarifies support from the Ohio State University Comprehensive Cancer Center.
Dynamic biomarkers are lacking in current anti-angiogenic strategies, leading to suboptimal results.
The DRD2–VEGF-A feedback loop may provide a new paradigm in cancer treatment.
Clinical Implications
Clinicians should be aware of the importance of accurate funding disclosures when interpreting research.
Conclusion
The correction emphasizes the need for precise funding information in research publications.
